卵巢-附件影像报告与数据系统(O-RADS)超声2019版:在病理确诊附件肿块中的前瞻性验证及与更新版(2022版)的比较
这项前瞻性研究纳入三家机构2022年1月至2023年12月连续977例疑似附件肿块女性,由三名有经验放射科医师按O-RADS超声2019版分类,并回顾性按2022版分类,以组织病理为参考标准。最终分析803例女性855个附件肿块(219个恶性,25.6%;636个良性,74.4%)。两版均有良好诊断准确性,2022版在准确性、敏感度和特异度上略高于2019版,观察者间一致性两版均完美(κ=0.96-0.97)。
要点
- O-RADS超声2019版与2022版对附件肿块恶性预测均具良好诊断准确性,AUC分别为0.906-0.923与0.919-0.936。
- 2022版较2019版准确性略高(82.5-86.7% vs 80.7-85.3%),敏感度93.6-95.0% vs 92.2-94.1%,特异度78.1-84.1% vs 76.1-82.9%。
- 两版总体O-RADS分类观察者间一致性均完美(Fleiss κ=0.96-0.97)。
核心结论
- O-RADS超声分类系统在预测附件肿块恶性方面显示良好诊断准确性和可靠性,更新版2022较2019版有适度提升。
研究设计与样本
- 前瞻性研究,纳入三家机构2022年1月至2023年12月连续977例疑似附件肿块女性,最终分析803例女性855个附件肿块(219个恶性,25.6%;636个良性,74.4%);由三名有经验放射科医师行超声检查并按O-RADS超声2019版分类,同一组医师回顾存储超声图像提供2022版分类;以组织病理为参考标准;用Fleiss κ检验评估观察者间一致性。
诊断标准与关键数值
- O-RADS超声2019版AUC 0.906-0.923,2022版AUC 0.919-0.936;2022版准确性82.5-86.7% vs 2019版80.7-85.3%,敏感度93.6-95.0% vs 92.2-94.1%,特异度78.1-84.1% vs 76.1-82.9%;两版总体O-RADS分类观察者间一致性Fleiss κ=0.96-0.97。
临床应用与阅片要点
- 作者指出更新版O-RADS超声2022版为附件肿块提供改进的风险分层,增强诊断信心,支持更精确的临床决策,并通过及时干预或量身定制的管理策略改善卵巢癌诊疗中的患者结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the diagnostic accuracy and reliability of the Ovarian-Adnexal Reporting and Data System (O-RADS) ultrasound v2019 in classifying adnexal masses (AMs) and compare the old and updated systems (v2022).
PATIENTS AND METHODS: This prospective study enrolled 977 consecutive women with suspected AMs from three institutions between January 2022 and December 2023. Ultrasound examinations were performed by three experienced radiologists who categorized AMs according to O-RADS ultrasound v2019. The same radiologists retrospectively reviewed the stored ultrasound images and provided the O-RADS ultrasound v2022 classification. Histopathology was used as the reference standard to calculate the diagnostic accuracy of the O-RADS versions in predicting malignant AMs. Inter-observer agreement (IOA) of the O-RADS scoring results was evaluated using the Fleiss kappa (κ) test.
RESULTS: The final analysis included 803 women with 855 AMs (219 (25.6%) malignant and 636 (74.4%) benign). Both O-RADS versions demonstrated good diagnostic accuracy, with area under the curve (AUC) values ranging from 0.906 to 0.923 (v2019) and 0.919 to 0.936 (v2022). The updated v2022 showed a slightly higher accuracy (82.5-86.7% vs. 80.7-85.3%), sensitivity (93.6-95.0% vs. 92.2-94.1%), and specificity (78.1-84.1% vs. 76.1-82.9%) compared to v2019. The IOA for the overall O-RADS classification was perfect for both versions (κ = 0.96-0.97).
CONCLUSIONS: The O-RADS ultrasound classification system demonstrated good diagnostic accuracy and reliability in predicting malignant AMs, with the updated v2022 showing modest improvements.
KEY POINTS: Question Accurate classification of adnexal masses is essential for management. Can updated O-RADS ultrasound v2022 improve diagnostic accuracy and reliability compared to v2019 in predicting malignancies? Findings O-RADS ultrasound v2022 demonstrated slightly higher diagnostic accuracy for identifying malignant adnexal masses compared to v2019, reflecting modest improvements in risk stratification and clinical decision-making. Clinical relevance The updated O-RADS ultrasound v2022 provides improved risk stratification for adnexal masses, enhancing diagnostic confidence, supporting more precise clinical decision-making, and improving patient outcomes through timely intervention or tailored management strategies in ovarian cancer care.
引用
- Almalki YE, Basha MAA, Nada MG, et al. Ovarian-Adnexal Imaging-Reporting and Data System (O-RADS) ultrasound version 2019: a prospective validation and comparison to updated version (v2022) in pathologically confirmed adnexal masses. Eur Radiol. 2024. PMID: 39604652. doi:10.1007/s00330-024-11235-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。